Browsing Tag
Bain Capital
25 posts
Man Group’s Abu Dhabi licence push strengthens ADGM’s claim in the global asset management race
Man Group wants a deeper Abu Dhabi base. ADGM’s asset management race is turning into a test of where global capital wants to sit next.
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now.
Insilico Medicine just doubled down on CNS with Tenacia. Here’s why that matters now.
Insilico Medicine has expanded its Tenacia CNS partnership in a deal worth up to $94.75 million. Read what it signals for AI drug discovery now.
Bridgepoint and Triton walk away from Spire Healthcare (LSE: SPI) as board keeps formal sale process alive with remaining bidders
Bridgepoint and Triton have walked away from Spire Healthcare's sale process. Find out what it means for SPI shareholders and what happens next. Read more.
Perpetual (ASX: PPT) to sell wealth management unit to Bain Capital for A$500m as private equity bets on Australia’s growing advice market
Perpetual agrees to sell its A$21.9bn wealth management arm to Bain Capital for A$500m. What this means for PPT shareholders and Australia's advice market. Read more.
OpenText to sell Vertica to Rocket Software as leadership transition sharpens enterprise AI focus
OpenText Corporation is divesting Vertica and appointing a new chief executive officer. Find out what this reset means for enterprise AI, debt reduction, and investors.
Bain Capital takes control of FineToday Holdings in private equity-to-PE deal
Bain Capital acquires FineToday from CVC Capital Partners, signaling a new chapter for the Japan-based personal care brand. Find out what this deal means.
Why Bain Capital is betting $344m on this Korean yoga wear brand’s global rise
Bain Capital acquires Korean athleisure brand Andar for $344M. Find out why this deal signals private equity’s next move in wellness fashion.
Bain Capital’s $400m SPAC IPO: Why $10 pricing could define its investor appeal in 2025
Bain Capital’s $400M SPAC IPO at $10 per unit sets a cautious but confident tone for 2025. Explore structure, risks, and investor sentiment now.
Inside CapVest’s acquisition of STADA: What changes after Bain Capital and Cinven?
CapVest is acquiring majority control of STADA from Bain and Cinven. Find out how this move could reshape the pharma giant’s global growth strategy.